1. Home
  2. HUM vs UTHR Comparison

HUM vs UTHR Comparison

Compare HUM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Humana Inc.

HUM

Humana Inc.

N/A

Current Price

$178.26

Market Cap

22.5B

Sector

Health Care

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$529.51

Market Cap

20.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HUM
UTHR
Founded
1961
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
20.4B
IPO Year
2002
1999

Fundamental Metrics

Financial Performance
Metric
HUM
UTHR
Price
$178.26
$529.51
Analyst Decision
Hold
Buy
Analyst Count
20
13
Target Price
$241.60
$524.62
AVG Volume (30 Days)
2.0M
355.5K
Earning Date
05-13-2026
05-28-2026
Dividend Yield
1.98%
N/A
EPS Growth
N/A
13.07
EPS
9.84
27.86
Revenue
$129,664,000,000.00
$1,483,300,000.00
Revenue This Year
$24.46
$7.77
Revenue Next Year
$6.58
$11.11
P/E Ratio
$18.24
$17.13
Revenue Growth
10.11
2.38
52 Week Low
$169.61
$266.98
52 Week High
$315.35
$537.19

Technical Indicators

Market Signals
Indicator
HUM
UTHR
Relative Strength Index (RSI) 36.42 62.18
Support Level $171.43 $463.64
Resistance Level $192.01 N/A
Average True Range (ATR) 6.43 19.01
MACD 2.26 1.77
Stochastic Oscillator 26.66 89.21

Price Performance

Historical Comparison
HUM
UTHR

About HUM Humana Inc.

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: